Outlook Therapeutics Aktie (A2PF3C | OTLK

Was macht Outlook Therapeutics?

Unternehmensprofil

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Chart der Outlook Therapeutics Aktie

Charttool öffnen

Aktuelle Nachrichten zu Outlook Therapeutics

Weitere Nachrichten

Das berichten andere über Outlook Therapeutics

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29th at 2:00 PM ET Live webcast on Wednesday, January 29th at 2:00 PM ET

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook...